Irritable Bowel Syndrome | Treatment Algorithms: Claims Data Analysis | IBS-Diarrhea | US | 2022

characterized by alterations in motility, stool consistency and frequency, and urgency. It is generally classified into three subtypes: constipation 
predominant, diarrhea predominant, and mixed; this analysis focuses on IBS-D, the diarrhea-predominant subtype. Limited treatment options are available for 
IBS, and only a few drugs have secured FDA approval for IBS-D. Current prescribing among recently treated and newly diagnosed IBS-D patients?
 * How have Viberzi and Lotronex been integrated into the treatment algorithm, and what are their sources of business?
 * What percentage of IBS-D patients receive drug therapy within 365 days
*Markets covered:* United States
*Key companies:* AbbVie, Salix, Sebela Pharmaceuticals
*Key drugs:* Viberzi, Xifaxan, Lotronex, dicyclomine, hyoscyamine sulphate / scopolamine, SSRIs, SNRIs, tricyclic agents, diphenoxylate
characterized by alterations in motility, stool consistency and frequency, and urgency. It is generally classified into three subtypes: constipation 
predominant, diarrhea predominant, and mixed; this analysis focuses on IBS-D, the diarrhea-predominant subtype. Limited treatment options are available for 
IBS, and only a few drugs have secured FDA approval for IBS-D. Current    prescribing among recently treated and newly diagnosed IBS-D patients?
 * How have Viberzi and Lotronex been integrated into the treatment algorithm, and what are their sources of business?
 * What percentage of IBS-D patients receive drug therapy within 365 days
*Markets covered:* United States
*Key companies:* AbbVie, Salix, Sebela Pharmaceuticals
*Key drugs:* Viberzi, Xifaxan, Lotronex, dicyclomine, hyoscyamine sulphate / scopolamine, SSRIs, SNRIs, tricyclic agents, diphenoxylate